COSMHealthcare · Medical Distribution

COSM Stock Forecast: Cosmos Health, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026

$0.24

+8.80% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$13.4M

Ticker Nerd rank

23 / 100

Median analyst target

$4.50

Analysts covering

Total return, dividends reinvested

+13.5%

−0.8%

YTD

−52.8%

−72.8%

From 52W high

−81.2%

From 52W low

+36.6%

$0.17

$1.25

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

COSM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cosmos Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Revisions

Growth

Momentum

Value

Quality

Volatility

Issuance

Size (91): Smaller than most of the companies we track.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Cosmos Health, Inc. — and when they’d sell — is the membership.

Wall Street

COSM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COSM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

COSM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

EPS revision, 90 days

−87.5%

Analysts raising

Analysts cutting

Fundamentals

Cosmos Health, Inc. (COSM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.3×
Price / sales: 0.2×
Price / book: 0.5×
EV / EBITDA: −1.7×

Growth & margins

Revenue growth (YoY): 30.7%
Earnings growth (YoY): 30.7%
Gross margin: 7.7%
Operating margin: −12.2%
Net margin: −30.4%

Returns & dividend

Return on equity: −92.3%
Return on assets: −18.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

COSM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution

Company	Market cap	TKN rank
COSMCosmos Health, Inc.	$13.4M	23
MEDSDataMeds AI, Inc.	$7.9M	15
SNYRSynergy CHC Corp.	$2.6M	47
ACHAccendra Health, Inc.	$238.7M	42
MODDModular Medical, Inc.*	$12.9M	11
AEONAEON Biopharma, Inc.*	$12.9M	47
PTNPalatin Technologies, Inc.*	$13.1M	54

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COSM appears on the weeks it earns a place.

News

Latest COSM news & analysis

Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

GlobeNewsWire · 27 July 2026positive

Cosmos Health announced it is developing a flexible, technology-driven subscription platform for its consumer health products, serving both consumer (B2C) and corporate (B2B) channels, with options including a free nutritionist consultation, an AI-powered assistant, or building a custom package.

Why it matters — The subscription platform represents a significant step in Cosmos Health's technology-driven transformation, expands its revenue channels through both B2C and B2B offerings, and builds on early success with the NOOR Collagen subscription showing a repeat purchase rate above 60%.

FAQ

Frequently asked questions about COSM stock

How does Ticker Nerd's model rank COSM?

As at 1 Aug 2026, Cosmos Health, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

What is the COSM stock forecast for 2030?

No analyst covering Cosmos Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.5 to $4.5 over the next 12 months.

How has COSM stock performed over the past year?

Cosmos Health, Inc. returned -72.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cosmos Health, Inc. do?

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group specializing in pharmaceuticals, nutraceuticals, healthcare services, and digital assets.

What is the latest news on COSM?

The most recent item we track (GlobeNewsWire, 27 July 2026): "Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels". Cosmos Health announced it is developing a flexible, technology-driven subscription platform for its consumer health products, serving both consumer (B2C) and corporate (B2B) channels, with options including a free nutritionist consultation, an AI-powered assistant, or building a custom package.

Company

About Cosmos Health, Inc.

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group specializing in pharmaceuticals, nutraceuticals, healthcare services, and digital assets. The company engages in the importation, exportation, distribution, and sale of pharmaceutical products, including over-the-counter drugs, branded and generic medicines, vitamins, minerals, dietary supplements, medical devices, and baby products. It manufactures and markets proprietary brands such as Sky Premium Life, NOOR Collagen, C-Sept, C-Scrub antimicrobial cleansers, and Mediterranation, with operations spanning Europe, the United States, the UK, UAE, and other regions. Cosmos Health Inc. operates manufacturing facilities like Cana Laboratories for contract production, distribution networks including CosmoFarm with robotic automation for pharmacy logistics, and telehealth initiatives. It conducts research and development through platforms like Cloudscreen AI for drug repurposing, focusing on nutraceutical formulas, nanotechnology, and compounds targeting obesity and other disorders. Additionally, the company manages a digital asset treasury featuring Bitcoin and Ethereum holdings to diversify its balance sheet. Serving wholesalers, pharmacies, clinics, retailers like Tesco and Superdrug, and healthcare providers, Cosmos Health Inc. supports a broad ecosystem in wellness and medical distribution. Founded in 2009 and headquartered in Thessaloniki, Greece, it plays a key role in bridging manufacturing, innovation, and global supply chains in the healthcare sector.

CEO Mr. Grigorios Siokas · 163 employees · Greece · https://www.cosmoshealthinc.com